Iberoamerican Journal of Medicine
https://iberoamjmed.com/article/doi/10.53986/ibjm.2023.0005
Iberoamerican Journal of Medicine
Editorial

Use of polypill to improve therapeutic adherence and outcomes in adults with recent acute myocardial infarction: is it an effective strategy?

Uso de polipíldora para mejorar la adherencia terapéutica y los resultados en adultos con infarto agudo de miocardio reciente: ¿es una estrategia efectiva?

Yelson Alejandro Picón-Jaimes, María Margarita Garcés-Lince, Juan Fernando Gómez-Gómez, Omar Villamizar-Rueda

Downloads: 4
Views: 146


References

1. World Health Organization. Cardiovascular Disease [Internet]. Available in: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1 (Accessed Sep 2022).
2. Heller O, Somerville C, Suggs LS, Lachat S, Piper J, Aya Pastrana N, et al. The process of prioritization of non-communicable diseases in the global health policy arena. Health Policy Plan. 2019;34(5):370-83. doi: 10.1093/heapol/czz043.
3. Barrios V, Kaskens L, Castellano JM, Cosin-Sales J, Ruiz JE, Zsolt I, et al. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study. Rev Esp Cardiol (Engl Ed). 2017;70(1):42-9. doi: 10.1016/j.rec.2016.05.009.
4. Ros-Castelló V, Natera-Villalba E, Gómez-López A, Sánchez-Sánchez A, Chico-García JL, García-Madrona S, et al. Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients. Cerebrovasc Dis Extra. 2020;10(3):166-73. doi: 10.1159/000511064.
5. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387(11):967-77. doi: 10.1056/NEJMoa2208275.
6. Singh K, Crossan C, Laba TL, Roy A, Hayes A, Salam A, et al. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the
UMPIRE trial. Int J Cardiol. 2018;262:71-8. doi: 10.1016/j.ijcard.2018.03.082.
7. Ortega Oviedo SI, Vargas Rosero E. Degree of adherence to treatments in people with cardiovascular risk. Av Enferm. 2014; 32(1):25-32. doi: 10.15446/av.enferm.v32n1.46032.
8. Vejar M, Abufhele A, Varleta P, Araya MV, Escobar E, Fernández M, et al. Adherence to pharmacologic treatment in secondary prevention of cardiovascular disease. Rev Chil Cardiol. 2016; 35(3):270-82. doi: 10.4067/S0718-85602016000300010.
9. Mass-Hernández LM, Acevedo-Aguilar LM, Lozada-Martínez ID, Osorio-Agudelo LS, Maya-Betancourth JGEM, Paz-Echeverry OA, et al. Undergraduate research in medicine: A summary of the evidence on problems, solutions and outcomes. Ann Med Surg (Lond). 2022;74:103280. doi: 10.1016/j.amsu.2022.103280.
10. Lozada-Martinez ID, Suarez-Causado A, Solana-Tinoco JB. Ethnicity, genetic variants, risk factors and cholelithiasis: The need for eco-epidemiological studies and genomic analysis in Latin American surgery. Int J Surg. 2022;99:106589. doi: 10.1016/j.ijsu.2022.106589.
11. Pérez-Fontalvo NM, De Arco-Aragón MA, Jimenez-García JDC, Lozada-Martinez ID. Molecular and computational research in low- and middle-income countries: Development is close at hand. J Taibah Univ Med Sci. 2021;16(6):948-9. doi: 10.1016/j.jtumed.2021.06.010.


Submitted date:
10/24/2022

Reviewed date:
11/19/2022

Accepted date:
12/02/2022

Publication date:
12/03/2022

638b45dfa9539538906c82b4 iberoamericanjm Articles
Links & Downloads

Iberoam J Med

Share this page
Page Sections